Michael Rome
Managing Director & Head of Therapeutics Investing at Foresite Capital
Los Angeles Metropolitan Area
Overview
Work Experience
Managing Director
2016 - Current
Foresite Capital is a healthcare and life sciences investment firm.
Board Member
2023
Board Observer
2023
CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
Raised $317,570,000.00 from Foresite Capital, TCG Crossover, RA Capital Management, Longitude Capital, Janus Henderson Investors, Malin Corporation, Acorn Bioventures, Avidity Partners, Biotechnology Value Fund and Ally Bridge Group.
Board Member
2022
Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.
Raised $731,850,004.00 from New Enterprise Associates, Deep Track Capital, TF Capital, SR One, Foresite Capital, Lilly Asia Ventures, Delos Capital, Quan Capital, OrbiMed and Sofinnova Investments.
Board Member
2018
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.
Raised $194,500,000.00 from Vida Ventures, Fidelity, RA Capital Management, Foresite Capital, Leerink Partners, Logos Capital, Venrock Healthcare Capital Partners, Nextech Invest, Boxer Capital and OrbiMed.
Board Member and Observer
2021
Alumis is a precision medicines company.
Board Member
2020
Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.
Raised $211,000,000.00 from Surveyor Capital, The Column Group, Atlas Venture, Alexandria Venture Investments, Casdin Capital, ARCH Venture Partners, Foresite Capital, WTT Investment and Willett Advisors LLC.
Board Member
2021 - 2023
Board Observer
2021 - 2022
Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.
Raised $377,487,455.00 from CARB-X.
Board Observer
2018 - 2019
Co-led series D financing